Maximizing Outcome of Multiple Sclerosis Transplantation
Status:
Terminated
Trial end date:
2019-10-09
Target enrollment:
Participant gender:
Summary
Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell
transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin
(rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).